2024-05-17
On May 13, Takeda announced that it has entered into A worldwide exclusive option and license agreement with AC Immune for ACI-24.060, a vaccine product targeting Aβ. ACI-24.060 is an anti-Aβ immunotherapy candidate designed to induce A strong antibody response against toxic Aβ, which is thought to drive plaque formation and Alzheimer's disease progression. By inducing plaque clearance and effectively inhibiting plaque formation in the brain, ACI-24.060 has the potential to delay the progression of Alzheimer's disease。